Literature DB >> 10971600

Glyceryl trinitrate induced headache in migraineurs - relation to attack frequency.

I Christiansen1, D Daugaard, L Lykke Thomsen, J Olesen.   

Abstract

Glyceryl trinitrate, a prodrug of nitric oxide, induces a mild to moderate headache in healthy subjects, whilst migraineurs develop a more severe headache, resembling spontaneous migraine attacks. In order to investigate whether this increased nitric oxide sensitivity depends upon the frequency of spontaneously occurring migraine attacks, intravenous infusion of glyceryl trinitrate (0.5 microg/kg/min) was given to 15 migraine patients with rare attacks (</=4 attacks/year) of migraine without aura. Fourteen age-matched migraine patients with frequent attacks of migraine without aura (>/=12 attacks/year) and 14 healthy subjects served as controls. No significant difference between the migraine groups for any of several parameters was detected, although the trend was always towards more headaches in frequent migraineurs. Both migraineurs with frequent and rare attacks experienced a headache that was significantly more severe, longer lasting, and fulfilled the diagnostic criteria for migraine without aura more often, compared to the healthy subjects (P = 0.0001). Conclusively, supersensitivity to glyceryl trinitrate in migraineurs seems to be related to a basic - probably genetically determined - pathophysiological mechanism involving nitric oxide, and not to the environmental influences, which to a large extent determine the expression of migraine.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10971600     DOI: 10.1046/j.1468-1331.2000.00094.x

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  16 in total

Review 1.  Headache-type adverse effects of NO donors: vasodilation and beyond.

Authors:  G Bagdy; P Riba; V Kecskeméti; D Chase; G Juhász
Journal:  Br J Pharmacol       Date:  2010-03-19       Impact factor: 8.739

Review 2.  Nitric oxide-related drug targets in headache.

Authors:  Jes Olesen
Journal:  Neurotherapeutics       Date:  2010-04       Impact factor: 7.620

Review 3.  Modelling headache and migraine and its pharmacological manipulation.

Authors:  S E Erdener; T Dalkara
Journal:  Br J Pharmacol       Date:  2014-07-01       Impact factor: 8.739

4.  Psilocybin dose-dependently causes delayed, transient headaches in healthy volunteers.

Authors:  Matthew W Johnson; R Andrew Sewell; Roland R Griffiths
Journal:  Drug Alcohol Depend       Date:  2011-11-29       Impact factor: 4.492

Review 5.  Verisimilitude (or "truthlikeness") as an alternative to pro and cons: migraine and cluster headache mechanisms.

Authors:  Peer Carsten Tfelt-Hansen
Journal:  J Headache Pain       Date:  2010-07-07       Impact factor: 7.277

6.  Spontaneous trigeminal allodynia in rats: a model of primary headache.

Authors:  Michael L Oshinsky; Menka M Sanghvi; Christina R Maxwell; Dorian Gonzalez; Rebecca J Spangenberg; Marnie Cooper; Stephen D Silberstein
Journal:  Headache       Date:  2012-09-10       Impact factor: 5.887

7.  sec-Butylpropylacetamide (SPD) has antimigraine properties.

Authors:  Dan Kaufmann; Emily A Bates; Boris Yagen; Meir Bialer; Gerald H Saunders; Karen Wilcox; H Steve White; K C Brennan
Journal:  Cephalalgia       Date:  2015-11-13       Impact factor: 6.292

8.  Nitric oxide release from trigeminal satellite glial cells is attenuated by glial modulators and glutamate.

Authors:  Jens Christian Laursen; Brian Edwin Cairns; Ujendra Kumar; Rishi Kumar Somvanshi; Xu-Dong Dong; Lars Arendt-Nielsen; Parisa Gazerani
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2013-12-15

Review 9.  Secondary headaches: secondary or still primary?

Authors:  Christoph J Schankin; Andreas Straube
Journal:  J Headache Pain       Date:  2012-04-01       Impact factor: 7.277

10.  The chronobiology of migraine: a systematic review.

Authors:  Amanda Holmen Poulsen; Samaira Younis; Janu Thuraiaiyah; Messoud Ashina
Journal:  J Headache Pain       Date:  2021-07-19       Impact factor: 7.277

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.